Exploring the Value of Biomarkers in Drug Discovery

The latest addition to Quotient Bioresearch’s ongoing ‘Evidence’ information series is now available for download. Biomarkers in Respiratory Disease – Part 1: Chronic Obstructive Pulmonary Disease (COPD) is the first white paper in a new series that will explore the value that biomarkers can add to drug discovery and development in important therapeutic areas.

The programme includes print and e-newsletters that regularly review the company’s scientific publications, as well as presentations on Quotient Bioresearch expertise and unique integrated clinical service offering – Synthesis-to-Clinic™.

COPD is a global health issue that continues to be an important cause of morbidity, mortality, and health-care costs worldwide. In the UK, for example, it affects as many as three million people and is soon to be the subject of a new National Clinical Strategy approach from government and healthcare providers.

Understanding disease progression – and developing successful therapeutic interventions – requires extensive use of biomarkers. The new Quotient Bioresearch white paper discusses how the combination of biomarkers from three sub-pathologies (oxidative stress, inflammation and tissue remodelling) with physiological assessment of lung function may provide an early indication of disease modification, the long-time goal of many current and prospective COPD treatments.